CD8A and neoplasm: Besides, the administration of αVISTA (VISTA mAb) shows similar anti-tumor effect in the B16OVA melanoma model, where the count of CD4+ T cells and CD8+ T cells increased (6.38% to 11.74%, 9.25% to 17.74%, respectively), and the percentage of MDSCs significantly decreased (37.74% to 25.64).